Test longer dosing of omalizumab for chronic hives
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This Phase 4 study looks at whether extending the time between omalizumab injections can still control chronic spontaneous hives (CSU). It may help some people need fewer injections while keeping symptoms under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have chronic spontaneous urticaria (CSU), confirmed by guideline-based diagnosis
- You have never taken omalizumab before starting this study
- You take four antihistamine tablets (or equivalents) every day for hives
- A clinician says you’re eligible for omalizumab based on local (Danish) guidelines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This trial tests a new medication (HRS-3095) for chronic spontaneous urticaria—persistent hives that don't go away despite taking standard antihistamine pills. If your hives have lasted months and remain poorly controlled, this study may help you find relief.
This trial tests a new medication (HS-10561) first in healthy adults to check safety, then in people with chronic spontaneous urticaria (long-term hives without a known cause) to see if it helps reduce symptoms. It may be an option for those who have had hives for at least 6 months.
This study is a long-term extension of the barzolvolimab trial for people with chronic spontaneous urticaria (CSU). It tests the continued safety and effectiveness of barzolvolimab over a longer period for those who have already completed the initial phase 3 study.
This study looks at how diet and oxidative stress (a type of cell damage) affect the severity of chronic hives and how well patients respond to the medication omalizumab (Xolair). It may help find ways to improve treatment by understanding these factors.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.